Načítá se...
Phase 0 - Microdosing strategy in clinical trials
Drug development is an activity that is long, complex and expensive. In 2004, attrition in the drug development paradigm prompted the US Food and Drug Administration (FDA) to introduce its ‘Critical Path’ document, which highlighted the serious discordance between major scientific advances and limit...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Medknow Publications
2008
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3025138/ https://ncbi.nlm.nih.gov/pubmed/21279177 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0253-7613.45147 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|